Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

BACKGROUND: Fabry disease is frequently characterized by gastrointestinal symptoms, including diarrhea. Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations. METHODS: We evaluated minimal clinically important differen...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Orphanet J Rare Dis
Main Authors: Schiffmann, Raphael, Bichet, Daniel G., Jovanovic, Ana, Hughes, Derralynn A., Giugliani, Roberto, Feldt-Rasmussen, Ulla, Shankar, Suma P., Barisoni, Laura, Colvin, Robert B., Jennette, J. Charles, Holdbrook, Fred, Mulberg, Andrew, Castelli, Jeffrey P., Skuban, Nina, Barth, Jay A., Nicholls, Kathleen
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923014/
https://ncbi.nlm.nih.gov/pubmed/29703262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0813-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki